Tag: ESMO 2016

October 11, 2016

Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab

Peregrine Pharmaceuticals, a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies...
October 10, 2016

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® In Advanced Renal Cell Carcinoma

Pfizer today announced data from an ongoing, investigational Phase 1b study of INLYTA® combined with the checkpoint inhibitor pembrolizumab, a...
October 10, 2016

TRACON Pharmaceuticals Presents Final Updated Phase 1b Results for TRC105

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet...
October 10, 2016

Ipsen and Exelixis Announce Positive Results from Phase 2 CABOSUN Trial

Ipsen and Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously...
October 7, 2016

Myriad Announces Four Poster Presentations at the 2016 ESMO Annual Meeting

Myriad Genetics, a leader in molecular diagnostics and personalized medicine, today announced that four poster presentations will be featured at...
October 5, 2016

Karyopharm to Present Updated SIGN Phase 2 Clinical Data at ESMO

Karyopharm Therapeutics, a clinical-stage pharmaceutical company, today announced that an oral presentation highlighting updated clinical data from the Company’s ongoing...
September 30, 2016

Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at ESMO 2016

Galena Biopharma, a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical...